image
Integer Holdings Corporation ITGR
Healthcare - Medical - Devices - NYSE - US
Watchlist
$ 121.0
-0.157 %
$ 4.22 B
Market Cap
56.54
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ITGR stock under the worst case scenario is HIDDEN Compared to the current market price of 121 USD, Integer Holdings Corporation is HIDDEN

ITGR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ITGR stock under the base case scenario is HIDDEN Compared to the current market price of 121 USD, Integer Holdings Corporation is HIDDEN

ITGR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ITGR stock under the best case scenario is HIDDEN Compared to the current market price of 121 USD, Integer Holdings Corporation is HIDDEN

ITGR Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ITGR

image
1M 0%
6M -11%
1Y 5%
3Y 74%
5Y 82%
All
$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
1.72 B REVENUE
7.51%
Growth Rates
1Year 7.51%
3Years 12.02%
5Years 6.41%
7Years 2.32%
10Years 9.58%
208 M OPERATING INCOME
24.45%
Growth Rates
1Year 24.45%
3Years 15.34%
5Years 5.73%
7Years 5.90%
10Years 10.66%
120 M NET INCOME
32.26%
Growth Rates
1Year 32.26%
3Years 7.39%
5Years 4.47%
7Years 8.74%
10Years 8.01%
205 M OPERATING CASH FLOW
13.87%
Growth Rates
1Year 13.87%
3Years 9.41%
5Years 4.41%
7Years 4.64%
10Years 9.70%
-195 M INVESTING CASH FLOW
-19.62%
Growth Rates
1Year -19.62%
3Years 10.33%
5Years -27.12%
7Years -22.23%
10Years -18.46%
13.3 M FINANCING CASH FLOW
173.95%
Growth Rates
1Year 173.95%
3Years -45.43%
5Years 16.14%
7Years 11.33%
10Years 22.49%
437 M REVENUE
-2.69%
Growth Rates
1Year 7.51%
3Years 12.02%
5Years 6.41%
7Years 2.32%
10Years 9.58%
49.6 M OPERATING INCOME
-13.12%
Growth Rates
1Year 24.45%
3Years 15.34%
5Years 5.73%
7Years 5.90%
10Years 10.66%
-22.5 M NET INCOME
-68.76%
Growth Rates
1Year 32.26%
3Years 7.39%
5Years 4.47%
7Years 8.74%
10Years 8.01%
31.3 M OPERATING CASH FLOW
-50.54%
Growth Rates
1Year 13.87%
3Years 9.41%
5Years 4.41%
7Years 4.64%
10Years 9.70%
-197 M INVESTING CASH FLOW
-665.72%
Growth Rates
1Year -19.62%
3Years 10.33%
5Years -27.12%
7Years -22.23%
10Years -18.46%
152 M FINANCING CASH FLOW
284.17%
Growth Rates
1Year 173.95%
3Years -45.43%
5Years 16.14%
7Years 11.33%
10Years 22.49%
Balance Sheet Integer Holdings Corporation
image
Current Assets 671 M
Cash & Short-Term Investments 46.5 M
Receivables 349 M
Other Current Assets 276 M
Non-Current Assets 2.41 B
Long-Term Investments 0
PP&E 580 M
Other Non-Current Assets 1.83 B
11.34 %8.95 %18.83 %59.37 %Total Assets$3.1b
Current Liabilities 227 M
Accounts Payable 101 M
Short-Term Debt 10 M
Other Current Liabilities 116 M
Non-Current Liabilities 1.23 B
Long-Term Debt 980 M
Other Non-Current Liabilities 251 M
6.96 %7.93 %67.19 %17.24 %Total Liabilities$1.5b
EFFICIENCY
Earnings Waterfall Integer Holdings Corporation
image
Revenue 1.72 B
Cost Of Revenue 1.26 B
Gross Profit 459 M
Operating Expenses 251 M
Operating Income 208 M
Other Expenses 88.3 M
Net Income 120 M
2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m002b(1b)459m(251m)208m(88m)120mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
26.74% GROSS MARGIN
26.74%
Averages
1Year 26.74%
3Years 26.34%
5Years 26.65%
7Years 27.33%
10Years 27.49%
12.13% OPERATING MARGIN
12.13%
Averages
1Year 12.13%
3Years 10.48%
5Years 10.76%
7Years 11.30%
10Years 9.81%
6.98% NET MARGIN
6.98%
Averages
1Year 6.98%
3Years 5.83%
5Years 6.52%
7Years 7.73%
10Years 5.81%
7.40% ROE
7.40%
Averages
1Year 7.40%
3Years 6.02%
5Years 6.26%
7Years 7.93%
10Years 6.29%
3.90% ROA
3.90%
Averages
1Year 3.90%
3Years 3.12%
5Years 3.27%
7Years 3.95%
10Years 3.00%
5.97% ROIC
5.97%
Averages
1Year 5.97%
3Years 5.05%
5Years 5.00%
7Years 5.23%
10Years 7.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Integer Holdings Corporation
image
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 120 M
Depreciation & Amortization 111 M
Capital Expenditures -106 M
Stock-Based Compensation 24.8 M
Change in Working Capital -54.6 M
Others 4.85 M
Free Cash Flow 99.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Integer Holdings Corporation
image
Wall Street analysts predict an average 1-year price target for ITGR of $150 , with forecasts ranging from a low of $144 to a high of $163 .
ITGR Lowest Price Target Wall Street Target
144 USD 19.01%
ITGR Average Price Target Wall Street Target
150 USD 24.38%
ITGR Highest Price Target Wall Street Target
163 USD 34.71%
Price
Max Price Target
Min Price Target
Average Price Target
170170160160150150140140130130120120110110100100Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Integer Holdings Corporation
image
Sold
0-3 MONTHS
44.6 M USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.41 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why Integer (ITGR) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 5 days ago
Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028 PLANO, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on July 1, 2025, and ending at the close of business on September 30, 2025. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company's common stock or a combination thereof, at the Company's election, in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes. globenewswire.com - 6 days ago
Integer Announces Conference Call to Discuss Second Quarter 2025 Results PLANO, Texas, June 26, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the second quarter ended June 27, 2025, on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. globenewswire.com - 1 week ago
ITGR vs. PEN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 2 weeks ago
Here's Why Integer (ITGR) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 3 weeks ago
ITGR or PEN: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two stocks is more attractive to value investors? zacks.com - 4 weeks ago
Zacks Industry Outlook Penumbra, Integer and AngioDynamics Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds. zacks.com - 4 weeks ago
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects. zacks.com - 1 month ago
Integer to Present at Truist Securities MedTech Conference on June 17 PLANO, Texas, June 03, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced participation in the 2025 Truist Securities MedTech Conference, to be held June 17, 2025, in Boston. Members of the Integer executive leadership team will participate in a fireside chat on Tuesday, June 17, at 10:40 a.m. globenewswire.com - 1 month ago
ITGR vs. SONVY: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 1 month ago
Why Integer (ITGR) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
ITGR or SONVY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 2 months ago
8. Profile Summary

Integer Holdings Corporation ITGR

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.22 B
Dividend Yield 0.00%
Description Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Contact 5830 Granite Parkway, Plano, TX, 75024 https://www.integer.net
IPO Date Sept. 29, 2000
Employees 11000
Officers Mr. Diron Smith Executive Vice President & Chief Financial Officer Mr. John Harris Executive Vice President of Global Operations & Manufacturing Strategy Mr. Tom P. Thomas Vice President, Corporate Controller & Principal Accounting Officer Ms. Lindsay Krause Blackwood J.D. Senior Vice President, General Counsel, Chief Ethics & Compliance Officer and Corporate Secretary Mr. Kirk K. Thor Ph.D. Executive Vice President & Chief Human Resources Officer Mr. Andrew Senn President of Cardio & Vascular Mr. Payman Khales Chief Operating Officer Ms. Kristen Marie Stewart C.F.A. Director of Investor Relations Mr. Joseph W. Dziedzic President, Chief Executive Officer & Director Mr. Jim Stephens President of Cardiac Rhythm Management & Neuromodulation